Biogen And Eisai Launch LEQEMBI IQLIK Autoinjector For Early Alzheimer's In U.S.

Biogen has submitted a new offer for its drug Skyclarys to be covered by Ireland's HSE, which will be discussed by the HSE Senior Management Team. The drug, approved by the EMA and FDA, treats Friedreich's ataxia and was previously rejected on cost grounds. Biogen disputes the NCPE's cost estimates, citing a €280,000 annual cost per patient and a €134m-€163m five-year budget impact.

Eisai and Biogen announced the U.S. availability of LEQEMBI IQLIK, an autoinjector for initiating lecanemab-irmb treatment in early Alzheimer's disease. The subcutaneous injection offers at-home dosing, reducing clinic visits and healthcare resource use. The companies provide support resources for patients and healthcare providers.

LEO Pharma agreed to acquire worldwide rights to Tanabe Pharma’s dersimelagon for up to $435m. The late-stage oral drug completed Phase III, with an FDA NDA filed June 2026. Thermo Fisher and KYAN Technologies will collaborate on precision oncology using patient-derived tumoroids. Biogen’s felzartamab won China NMPA approval for multiple myeloma. Expedition Therapeutics raised $115m Series B for EXPD-101 COPD Phase II.

Biogen (Nasdaq: BIIB) and TJ Biopharma said China’s NMPA approved felzartamab, branded Jingfei, for multiple myeloma. The therapy is for adults who have had at least one prior treatment line, in combination with lenalidomide and dexamethasone. The approval is the drug’s first worldwide regulatory clearance, according to the companies.

Wolfe Research upgraded Biogen and AbbVie to Outperform, setting $300 price targets for each. For Biogen, it cited late-stage pipeline catalysts for litifilimab and felzartamab and said the Apellis acquisition strengthens near-term revenue. For AbbVie, it cited valuation, limited near-term loss-of-exclusivity risk, and multiple upcoming clinical catalysts.

Biogen (NASDAQ:BIIB) reported Q2 2026 revenue of $2.7B, up 3% year over year. GAAP EPS was $0.66, down from $4.33; non-GAAP EPS was $3.60, down 34%. Growth portfolio revenue rose to $1.1B. Full-year revenue guidance was revised to a mid-single-digit increase, and non-GAAP EPS guidance is $12.00 to $13.00. Net debt was $6.8B after the Apellis deal.